| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444918 | European Journal of Cancer | 2013 | 8 Pages |
Abstract
EMACP combination chemotherapy is an effective treatment for high-risk GTN, with a remission rate comparable to EMA/CO. However, the difference in duration of treatment is only slightly shorter with EMACP. Cisplatin-based chemotherapy in the form of EMACP in this study was not proven more effective than EMA/CO.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
C. Lybol, C.M.G. Thomas, E.A. Blanken, F.C.G.J. Sweep, R.H. Verheijen, A.M. Westermann, I.A. Boere, A.K.L. Reyners, L.F.A.G. Massuger, R.Q.G.C.M. van Hoesel, P.B. Ottevanger,